- Report
- February 2024
- 70 Pages
Japan
From €4486EUR$4,750USD£3,815GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4486EUR$4,750USD£3,815GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4486EUR$4,750USD£3,815GBP
- Report
- February 2024
- 90 Pages
Asia Pacific
From €4486EUR$4,750USD£3,815GBP
- Report
- February 2024
- 80 Pages
Latin America
From €4486EUR$4,750USD£3,815GBP
- Report
- February 2024
- 80 Pages
Europe
From €4486EUR$4,750USD£3,815GBP
- Report
- February 2024
- 181 Pages
Europe
From €4486EUR$4,750USD£3,815GBP
- Report
- February 2024
- 150 Pages
Global
From €4486EUR$4,750USD£3,815GBP
- Report
- August 2023
- 70 Pages
Africa, Middle East
From €4486EUR$4,750USD£3,815GBP
- Report
- August 2023
- 70 Pages
South Korea
From €4486EUR$4,750USD£3,815GBP
- Report
- October 2022
- 70 Pages
Africa
From €4486EUR$4,750USD£3,815GBP
- Report
- August 2023
- 150 Pages
North America
From €4486EUR$4,750USD£3,815GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €472EUR$500USD£402GBP
Byetta is a brand of exenatide, a drug used to treat type 2 diabetes. It is a member of the Endocrine and Metabolic Disorders Drugs market, which includes drugs used to treat a variety of conditions related to hormones and metabolism. Byetta is an injectable medication that helps to control blood sugar levels by increasing the amount of insulin released by the pancreas. It is typically used in combination with other diabetes medications.
The Endocrine and Metabolic Disorders Drugs market is a large and growing market, with a wide range of products available. Byetta is one of the most popular drugs in this market, and is used by millions of people around the world.
Companies in the Byetta market include Eli Lilly, Novo Nordisk, Sanofi, Merck, and AstraZeneca. Show Less Read more
